Join thousands of book lovers
Sign up to our newsletter and receive discounts and inspiration for your next reading experience.
By signing up, you agree to our Privacy Policy.You can, at any time, unsubscribe from our newsletters.
Frontmatter -- Contents -- Introduction / Ackermann, R. -- Transurethral prostatic surgery at the Mayo Clinic / Utz, D. C. -- Morphological aspects of the human prostate and the development of benign prostatic hyperplasia / Aumüller, G. -- Stem cell organization of the prostate and the development of benign prostatic hyperplasia / Isaacs, J. T. -- Benign prostatic hyperplasia: morphometric studies in relation to the pathogenesis / Bartsch, G. / Brüngger, A. / Schweikert, U. / Hintner, H. / Höpfl, R. / Rohr, H. P. -- The extracellular matrix and cellular proliferation in the etiology of benign prostatic hyperplasia / Mawhinney, M. -- Steroid hormones, receptors and benign prostatic hyperplasia / Romijn, J. C. -- Growth factors in benign prostatic hyperplasia / Lawson, R. K. / Story, M. T. / Jacobs, S. C. / Begun, F. P. -- Transurethral prostatectomy - complications / Bandhauer, K. -- Results of surgical management of BPH - TUR-P by cold punch technique / Bülow, H. -- Urodynamic implications of benign prostatic hyperplasia, parameters and suggestions for the set-up of prostatic studies / Jensen, K. M.-E. / Anderson, J. T. -- Conservative nonhormonal treatment of patients with benign prostatic hyperplasia / Dreikorn, K. / Richter, R. -- Management of benign prostatic hyperplasia with antiandrogens and antiestrogens - clinical results (Review) / Tenaglia, R. / Silverio, F. Di -- Androgen ablation in the treatment of stage II benign prostatic hyperplasia / Schröder, F. H. / Bosch, R. J. L. H. / Blom, J. H. M. -- Aromatase inhibitors in the management of benign prostatic hyperplasia / Tunn, U. W. / Schweikert, H. U. -- Closing remarks / Frohmüller, H. -- Contributors
Frontmatter -- Contents -- Opening remarks / Hannse, H. -- Prologue / Greenblatt, R. B. -- 1. Physiology and pathophysiology of the perimenopausal years -- Some aspects of oogenesis, follicular growth, and endocrine involution / Nocke, W. -- The climacteric syndrome / Schneider, H. P. G. -- Skin and the menopause / Brincat, M. -- Osteoporosis: occurrence and diagnosis / Lindsay, R. -- Lipids, hormonal status and the cardiovascular system in the postmenopause / Tikkanen, M. J. / Nikkila, E. A. / Kuusi, T. -- Psychosocial aspects in the perimenopause / Wenderlein, J. M. -- The bladder in the menopausal woman / Versi, E. -- Discussion -- 2. Management of the climacteric patient -- 2.1. General aspects -- The influence of nutrition and exercise / Notelovitz, M. -- Non-hormonal medication / Utian, W. H. -- Discussion -- 2.2. Hormonal treatment -- Selection of patients - kind and duration of treatment / Studd, J. W. W. / Andersen, H. M. / Montgomery, J. C. -- Routes of estrogen administration / Cardozo, L. -- Sex steroids and lipoproteins / Larsson-Cobn, U. / Wallentin, L. -- Discussion -- 2.3. Risk-benefit evaluation of hormonal therapy -- Prospective study on long term risk of hormone replacement therapy / Hunt, K. / Vessey, M. -- Long-term metabolic effects of estrogen therapy / Husmann, F. -- Hormonal replacement therapy and breast cancer / Gambrell, R. D. -- Prevention of endometrial abnormalities / Whitehead, M. I. -- Estrogen/progestogen as a prophylactic treatment of postmenopausal osteoporosis / Christiansen, C. -- Discussion -- 2.4. Special aspects in premenopausal women -- Management of the premenstrual syndrome / Magos, A. L. / Studd, J. W. W. -- Contraception in premenopausal age / Schwartz, U. -- Discussion -- Closing remarks / Crosignani, P. G. -- Epilogue / Greenblatt, R. B. -- List of contributors -- Backmatter
Frontmatter -- Welcome address / Flamigni, C. -- Contents -- Introduction / Haspels, A. A. / Vange, N. van der -- Antiandrogen therapy for signs of androgenization: an overview / Schindler, A. E. -- I. Pharmacology and physiology -- Pharmacological aspects of cyproterone acetate / Neumann, F. -- Pharmacokinetics of cyproterone acetate and ethinyl estradiol in smoking and non-smoking women during treatment with Diane-35 / Zurth, Chr. / Täuber, U. -- Ovulation inhibitory effect of SH B 209 AE (Diane-35)-a new antiandrogen-estrogen combination / Spona, J. / Huber, J. / Schmidt, J. B. -- A study to investigate the maintenance of ovulation inhibition when patients switch over from Diane to Diane-35 / Higgins, H. P. / Davies, T. G. / Hutchinson, P. E. -- Effect of a new antiandrogen-estrogen sub-fifty combination on the endometrium / Fedele, L. / Marchini, M. / Carinelli, S. G. / Zamberletti, D. / Baglioni, A. -- II. Polycystic ovary syndrome -- Endocrinological and clinical findings on the therapy with Diane-35 in polycystic ovary syndrome / Falsetti, L. / Casarotti, G. A. / Gastaldi, A. -- Discussion -- III. Effects on the haemostatic system -- Longitudinal study on the effects of a cyproterone acetate and ethinyl estradiol combination on haemostasis / Bruni, V. / Bucciantini, S. / Rosati, D. / Verni, A. / Abbate, R. / Pinto, S. -- Haemorheological effects of Diane-35 and Microgynon®-Preliminary results of a double blind study / Ernst, E. / Schmölzl, Ch. / Matrai, A. / Schramm, W. -- Antiandrogen treatment in women with acne: a controlled trial / Ashton, R. E. / Miller, J. A. / Wojnarowska, F. T. / Dowd, P. M. / O'Brien, T. J. / Griffiths, W. A. D. / Jacobs, H. S. -- IV Special aspects -- Clinical assessment of two antiandrogen treatments, cyproterone acetate combined with ethinyl estradiol and spironolactone in hirsutism / Rubens, R. / Vermeulen, A. -- Treatment of severe androgenization symptoms with Diane and intramuscularly applied cyproterone acetate (Androcur Depot) / Kaiser, E. -- One-year experience with a new oral contraceptive using natural estradiol and cyproterone acetate / Hirvonen, E. / Stenman, U.-H. / Vartiainen, E. -- Discussion -- V. Metabolic and clinical aspects -- Clinical and metabolic effects of a new estrogenantiandrogen low dose combination / Cecco, L. De / Capitanio, G. L. / Bertolini, S. / Croce, S. / Centonze, A. -- Effects of cyproterone acetate on serum lipoproteins when administered alone and in combination with ethinyl estradiol / Silfverstolpe, G. / Lindberg, U.-B. / Enk, L. / Samsioe, G. / Crona, N. -- Clinical, metabolic and endocrine effects of long term use of a cyproterone acetate and ethinyl estradiol combination in hyperandrogenized women / Gaspard, U. J. / Bonnivert, J. / Emonts, P. / Gillain, D. / Lambotte, R. -- Cyproterone acetate versus levonorgestrel combined with ethinyl estradiol in the treatment of acne : results of a multi-center study / Carlborg, L. -- Comparison of Diane-35 with Neo-Eunomin from the dermatological viewpoint / Nürnberger, F. -- A double blind comparative study of tetracycline and Diane, alone and in combination in the treatment of acne / Greenwood, R. / Brummitt, L. / Burke, B. / Cunliffe, W. J. -- The comparative efficacy and safety of Diane- 35 versus Diane-50 in the treatment of moderate to severe acne and seborrhea: preliminary results / Fugère, P. / Percival-Smith, R. K. L. / Lussier-Cacan, S. / Tétrault, C. / Farquhar, D. J. -- Results of an extended open phase m study with Diane-35 / Aydinlik, S. -- Discussion -- Closing remarks / Lachnit-Fixson, U. -- List of first-mentioned contributors
Frontmatter -- Contents -- I. Mechanism of hormonal action at cellular level and biochemistry -- Mechanism and effects of androgen withdrawal therapies / Bruchovsky, N. / Rennie, P. S. / Goldenberg, S. L. -- Target-cell response to androgen withdrawal / Voigt, K. D. / Klein, H. -- Effects of chronic treatment with an LH-RH agonist on human testis tissue / Huhtaniemi, I. T. -- Animal models for prostate cancer / Otto, U. / Wagner, B. / Kloppel, G. / Baisch, H. / Klosterhalfen, H. -- The significance of the nude mice model for studies on human prostatic carcinoma / Steenbrugge, G. J. van / Jong, F. H. de / Gallee, M. P. W. / Schroder, F. H. -- II. Etiology and experimental basis of therapy -- Etiology and natural history of early prostatic cancer / Schröder, F. H. -- Pharmacological basis of androgen deprivation by various antiandrogens and their combination with LH-RH agonists / Neumann, F. / El Etreby, M. F. / Habenicht, U.-F. / Radlmaier, A. / Bormacher, K. -- III. Clinics -- Evaluation of different endocrine approaches in the treatment of prostatic carcinoma / Turkes, A. O. / Peeling, W. B. / Wilson, D. W. / Griffiths, K. -- Rationale of total androgen blockade by cyproterone acetate / Tunn, U. W. -- Clinical experience with Androcur® in the treatment of prostatic cancer / Becker, H. / Klosterhalfen, H. -- Prostate cancer treatment: tolerance of different endocrine regimens / Varenhorst, E. -- Result of long-term treatment with cyproterone acetate (CPA) in advanced prostatic cancer patients / Di Silverio, F. / Sciarra, F. -- Results and experience with the androgen ablation therapy: current trends in the USA / Kirchheim, D. -- Long-term results of an LH-RH agonist monotherapy in patients with carcinoma of the prostate and reflections on the so-called total androgen blockade with pre-medicated cyproterone acetate / Jacobi, G. H. -- List of first-mentioned contributors
Sign up to our newsletter and receive discounts and inspiration for your next reading experience.
By signing up, you agree to our Privacy Policy.